Bio Impact Capital LLC Crinetics Pharmaceuticals, Inc. Transaction History
Bio Impact Capital LLC
- $540 Million
- Q1 2025
A detailed history of Bio Impact Capital LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 631,964 shares of CRNX stock, worth $18.9 Million. This represents 3.92% of its overall portfolio holdings.
Number of Shares
631,964
Previous 617,035
2.42%
Holding current value
$18.9 Million
Previous $31.5 Million
32.81%
% of portfolio
3.92%
Previous 4.72%
Shares
13 transactions
Others Institutions Holding CRNX
# of Institutions
235Shares Held
87MCall Options Held
40KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA9.31MShares$279 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$206 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$187 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$186 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$153 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.61B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...